← Alle mensen

MG

Mohamed Gamil

2 publicaties

PubMed → Google Scholar →

Publicaties op Oncologisch.com

Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-smal...
European journal of cancer (Oxford, England : 1990) · 9 september 2025
Subcutaan versus IV amivantamab plus lazertinib bij EGFR-gemuteerd NSCLC: PALOMA-3
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 20 oktober 2024